Inuvo GAAP EPS of -$0.28 misses by $0.09, revenue of $6.8M misses by $0.9M

Inuvo reported Q3 GAAP EPS of -$0.28, missing estimates by $0.09, and revenue of $6.8M, down 69.9% year-over-year and missing by $0.9M. The company expects revenue growth in Q4 2026. (INUV)

Original reporting
Published Nov 12, 2026, 9:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$INUV
Bearish
medium confidence
Mentioned
$INUV
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$INUVBearishLow
01

Why it matters

The earnings shortfall could trigger further price declines unless the company shows rapid revenue recovery.

02

Market read

Micro‑cap earnings miss with no guidance lift; likely negative sentiment for the stock and peers.

03

What to watch

Potential upside from upcoming audience modeling growth in Q4.

Relevance 6/10Novelty 6/10Timing: after market close

Background

Inuvo is a small AI‑driven advertising technology company listed on NASDAQ.

Company-level read

Ticker impact

$INUVBearishMedium confidence
Context

Inuvo reported Q3 GAAP EPS of -$0.28 and revenue of $6.8M, both missing expectations.

Expected impact

likely downward pressure as the market prices in the earnings miss

Evidence & confidence

Micro‑cap earnings miss typically triggers sell‑offs; no guidance improvement was provided.

Market effects

May weigh on other ad‑tech and AI‑driven marketing firms.

Limited to US small‑cap segment.

Minimal global impact.

Counterpoint

Some investors may view the miss as a buying opportunity if the stock is oversold.

Key entities

  • Inuvo, Inc.

    AI advertising technology firm reporting Q3 results.

Related articles

$INUVMed

Inuvo Inc (INUV) (Q2 2026) Earnings Call Highlights: Strategic Pivot to IntentKey Drives

Inuvo Inc (INUV) reported Q2 2026 results and discussed its shift from legacy search to IntentKey. CFO Wallace Ruiz said legacy search revenue fell 80% year over year to about $4.0 million, while audience modeling rose 19% to about $3.6 million, totaling $7.5 million. Management expects IntentKey to reach cash neutral to cash positive at mid-$20M revenue by 2027 and noted a signed but not yet funded government contract.

$INUVMedAI 8/10

Inuvo (INUV) Q2 2026 Earnings Call Transcript

Inuvo (INUV) reported Q2 2026 revenue of $7.5 million, down 67% year over year, with legacy search revenue falling 80% to $3.9 million. Audience modeling revenue rose 19% to $3.6 million. Gross margin was 44%. Net loss was $4.0 million ($0.27/share). The company said it raised $13 million to retire debt and fund IntentKey AI, and launched healthcare and recruitment pilots.

$INUVMed

Inuvo Reports Second Quarter 2026 Results

Inuvo, Inc. (INUV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Inuvo Reports Second Quarter 2026 Results Audience Modeling Revenue Grows 19% as Company Streamlines Legacy Search and Strengthens Capital Position Management to host conference call at 4:15 PM ET, Tuesday, August 11, 2026 LITTLE ROCK, AR, August 11, 2026 – Inuvo, In

$NOKMed

LightCounting:: November 2026 Nokia SReXperts

Nokia hosted its SReXperts/Wavelengths conference in November 2026, focusing on AI's impact on connectivity and its solutions for customers. The company reported strong Q3 2026 earnings, with AI & Cloud sales doubling year-over-year and $1.7 billion in new orders. Nokia expects 25-30% growth in its Optical and IP Networks businesses in 2027. The company aims to help telecom operators adapt to AI-driven changes and capitalize on new opportunities.

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.